SS
NRSN icon

SBI Securities’s NeuroSense Therapeutics NRSN Stock Holding History

SBI Securities’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184 Hold
13
– – ﹤0.01% 3350
2026
Q1 		$200 Sell
13
-60
-82% -$1.07K ﹤0.01% 3218
2025
Q4 		$1.12K Hold
73
– – ﹤0.01% 2603
2025
Q3 		$1.82K Sell
73
-150
-67% -$4.39K ﹤0.01% 2459
2025
Q2 		$8.42K Buy
223
+214
+2,378% +$6.2K ﹤0.01% 1777
2025
Q1 		$163 Hold
9
– – ﹤0.01% 3290
2024
Q4 		$210 Buy
+9
New +$207 ﹤0.01% 3225

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

SBI Securities's NRSN Position: Q2 2026 in Review

SBI Securities held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 13 shares worth $184. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

SBI Securities first reported a position in NRSN in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.42K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • SBI Securities held 13 shares of NeuroSense Therapeutics worth $184 as of Q2 2026.
  • SBI Securities left its NeuroSense Therapeutics share count unchanged in Q2 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3350 holding.
  • SBI Securities first reported a position in NeuroSense Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's NeuroSense Therapeutics position peaked at $8.42K in Q2 2025.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.